| Literature DB >> 23803418 |
Hannah Kendall Smith1, Kevin Lee Nelson, Edison S Calaunan, Arnold Lee Smith, Victoria Nguyen.
Abstract
BACKGROUND: Haemophilus influenzae is a human-restricted facultative anaerobe which resides mostly in the oropharynx. The majority of isolates recovered from the throat are unencapsulated commensals (NTHi), but depending on host susceptibility they cause bronchitis, otitis media and on occasion bacteremia and meningitis. Because of the variable oxygen availability in the various niche permitting bacterium replication, the organism must thrive in well oxygenated surfaces, such as pharyngeal epithelium to anoxic environments like the bottom of a Biofilm and in airway mucus. Other reports indicate that H. influenzae use aerobic respiration, anaerobic respiration and fermentation to generate ATP. To gain insight in to the activity of several classes of antibiotics against five well-characterized unencapsulated H. influenzae in room air, in 5% CO2 and under strict anaerobiosis. We also tested for the role of oxidative killing by all cidal antibiotics.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23803418 PMCID: PMC3723416 DOI: 10.1186/1756-0500-6-241
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Aerobic susceptibility in air
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| Rd KW20 | 0.33 | 0.54 | 0.29 | 2.31 | 22.5 | 22.5 | 5.25 | 225 | 1.40 | 1.40 | 0.70 | 2.8 | 0.18 | 0.26 |
| R2846 | 0.44 | 0.50 | 0.20 | 2.31 | 4.22 | 8.44 | 1.98 | 113 | 0.70 | 1.40 | 0.35 | 1.05 | 0.26 | 0.80 |
| R2866 | 900 | >1800 | 0.29 | 1.16 | 16.88 | 16.88 | 0.88 | 113 | 1.40 | 1.40 | 0.70 | 1.41 | 0.18 | 0.70 |
| R3642 | 675 | >1800 | 0.29 | 2.31 | 5.63 | 14.07 | 450 | 1800 | 1.06 | 2.11 | 0.53 | 0.70 | 0.14 | 1.05 |
| R3661 | 0.33 | 0.59 | 0.29 | 3.72 | 16.85 | 16.85 | 17.58 | 1800 | 1.41 | 2.80 | 0.70 | 1.75 | 0.18 | 1.05 |
*produces TEM β-lactamase.
Aerobic susceptibility in air
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| Rd KW20 | 0.51 | 3.00 | 11.72 | 5.63 | 5.63 | 16.88 | 0.48 | 1.93 | 70.0 | 70.0 | 0.71 | 3.94 |
| R2846 | 0.68 | 1.56 | 11.72 | 15.94 | 0.26 | 1.41 | 0.26 | 0.44 | 26.5 | 70.0 | 2.25 | 4.50 |
| R2866 | 0.72 | 1.56 | 15.94 | 24.37 | 2.81 | 5.63 | 0.26 | 0.44 | 70.0 | 105.5 | 1.69 | 3.10 |
| R3642 | 1.10 | 2.81 | 15.94 | 30.94 | 2.81 | 11.25 | 0.35 | 0.97 | 70.0 | 105.5 | 3.38 | 3.38 |
| R3661 | 0.85 | 4.07 | 12.19 | 14.06 | 4.22 | 22.50 | 0.53 | 1.41 | 35.0 | 70.0 | 1.41 | 4.50 |
Amp ampicillin, Tet tetracycline, Cip ciprofloxacin, Clar clarithromycin, Cfrx cefuroxime, Spec spectinomycin, Cclr Cefaclor, TMP trimethoprim, Rif rifampin, Kan Kanamycin, Tobr tobramycin, Cam chloramphenicol, Erm erythromycin.
Aerobic susceptibility in 5% CO
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| Rd KW20 | 1.17 | 1.41 | 0.35 | 5.63 | 22.5 | 33.85 | 9.10 | 338 | 4.22 | 5.63 | 2.82 | 4.22 | 0.27 | 0.8 |
| R2846 | 0.44 | 0.50 | 0.32 | 0.94 | 10.3 | 18.8 | 1.10 | 84.4 | 1.41 | 4.22 | 1.41 | 2.81 | 0.27 | 0.8 |
| R2866 | 1350 | >1800 | 0.32 | 2.81 | 26.3 | 33.8 | 0.88 | 113 | 1.4 | 1.4 | 2.11 | 2.81 | 0.27 | 0.8 |
| R3642 | 900 | >1800 | 0.25 | 0.32 | 5.63 | 14.1 | 788 | 1800 | 1.41 | 4.22 | 1.41 | 2.11 | 0.27 | 1.4 |
| R3661 | 1.41 | 2.81 | 0.29 | 2.83 | 18.8 | 22.5 | 4.39 | 1575 | 2.81 | 5.63 | 2.11 | 4.22 | 0.35 | 1.4 |
Aerobic susceptibility in 5% CO
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| Rd KW20 | 2.11 | 2.34 | 15.47 | 23 | 18.58 | 30 | 3.26 | 11.69 | 122.5 | 140 | 8.29 | 10.17 |
| R2846 | 1.14 | 4.22 | 11.7 | 18.7 | 0.35 | 14.10 | 0.49 | 0.57 | 70.0 | 87.5 | 8.29 | 12.04 |
| R2866 | 1.41 | 2.81 | 15.94 | 24.4 | 6.57 | 11.25 | 3.53 | 0.57 | 157 | 157 | 16.58 | 16.58 |
| R3642 | 1.88 | 5.63 | 23.4 | 30.9 | 7.5 | 30.0 | 0.35 | 1.41 | 87.5 | 105 | 10.6 | 16.58 |
| R3661 | 2.34 | 5.63 | 15.9 | 18.75 | 11.25 | 30.0 | 0.61 | 1.10 | 87.5 | 105 | 16.58 | 20.3 |
Amp ampicillin, Tet tetracycline, Cip ciprofloxacin, Clar clarithromycin, Cfrx cefuroxime, Spec spectinomycin, Cclr Cefaclor, TMP trimethoprim, Rif rifampin, Kan Kanamycin, Tobr tobramycin, Cam chloramphenicol, Erm erythromycin.
Anaerobic susceptibility
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| R3929 | 0.53 | 4.22 | 0.18 | 15.9 | 25.31 | 26.72 | 3.52 | 42.2 | 1.06 | 2.11 | 1.06 | 2.81 | 0.53 | 2.81 |
| R3931 | 1.41 | 4.22 | 0.35 | 2.11 | 18.28 | 45.0 | 0.88 | 5.25 | 3.17 | 18.7 | 4.13 | 6.56 | 0.53 | 2.81 |
| R3930 | 1575 | 1800 | 0.27 | 1.05 | 2.11 | 8.44 | 0.88 | 84.4 | 1.23 | 2.46 | 1.23 | 2.81 | 0.53 | 2.81 |
| R3932 | 1350 | 1800 | 0.35 | 2.81 | 1.46 | 2.34 | 562 | 675 | 1.29 | 1.64 | 1.28 | 1.87 | 0.70 | 2.81 |
| R3393 | 1.76 | 4.22 | 0.28 | 8.44 | 9.92 | 33.75 | 3.5 | 28.10 | 1.99 | 3.28 | 1.64 | 3.75 | 0.53 | 2.81 |
Anaerobic susceptibility
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| R3929 | 0.35 | 1.78 | 22.50 | 45 | 8.44 | 45.0 | 0.35 | 1.06 | 33.8 | 67.5 | 3.7 | 5.98 |
| R3931 | 0.68 | 1.56 | 11.25 | 45 | 11.25 | 33.75 | 0.53 | 1.41 | 78.8 | 123.8 | 7.0 | 7.14 |
| R3930 | 0.48 | 1.05 | 16.88 | 45 | 2.81 | 16.88 | 0.35 | 0.88 | 107 | 315 | 4.4 | 7.39 |
| R3932 | 1.10 | 19.69 | 8.44 | 45 | 11.25 | 33.75 | 0.35 | 1.41 | 14.1 | 28.1 | 15.5 | 28.48 |
| R3933 | 1.23 | 7.51 | 16.88 | 45 | 11.25 | 33.75 | 0.35 | 1.41 | 56.3 | 135 | 6.70 | 8.79 |
Amp ampicillin, Tet tetracycline, Cip ciprofloxacin, Clar clarithromycin, Cfrx cefuroxime, Spec spectinomycin, Cclr Cefaclor, TMP trimethoprim, Rif rifampin, Kan Kanamycin, Tobr tobramycin, Cam chloramphenicol, Erm erythromycin.
Figure 1A. Strain R2866 was incubated in room air with tetracycline at 2 μg/ml (■), or spectinomycin at 20 μg/ml (▲) with the number of CFU determined on aliquots obtained hourly. Strain R2846 was incubated with 3 μg/ml tetracycline (♦) or spectinomycin at 8 μg/ml (×) with the surviving CFU determined on aliquots obtained hourly. B. Strain R2866 was incubated anaerobically with tetracycline at 2 μg/ml (■), or spectinomycin at 20 μg/ml (▲) with the number of CFU determined on aliquots obtained hourly. Strain R2846 was incubated with 3 μg/ml tetracycline (♦) or spectinomycin at 8 μg/ml (×) with the surviving CFU determined on aliquots obtained hourly.
Figure 2Hydroxyl ions were detected during an aerobic time-kill assay in room air by measuring the fluorescence at 516of. 3′ (p-hydroxyphenyl), fluorescein (HPF, 5 μM)v Positive controls consisted of 1 mM H2O2 added to the media with strain R2866 (×) and R2846 (‡). Hydroxyl ions were not detected during incubation of R2866 with 2 μg/ml tetracycline (■) or Kanamycin at 1.5 μg/ml (▲) or with R2846 in media containing tetracycline at 3 μg/ml (•) or Kanamycin at 1.5 μg/ml (▼).
Figure 3Strain R2866 was incubated in room air with Kanamycin at 1 μg/ml (×) or tetracycline at 2 μg/ml (♦) in sBHI containing 10 μM bis(1,2-dibutylbarbituric acid) trimethine oxonol [DiBAC(3)] and the fluorescence measured at 530. Strain R2866 gradually lost membrane permeability during the incubation (●).
Antibiotics used
| Ampicillin | BP1760-25 | 965826 | Fisher Scientific |
| Cefaclor | SI-114 8A | XY5511 AMX | Eli Lilly |
| Cefuroxime | C4417-1G | 110M0794V | Sigma |
| Chloramphenicol | C-0378 | 44H0560 | Sigma |
| Ciprofloxacin HCl | 86393-320 | 9867 | Miles laboratories |
| Clarithromycin | C4502 | n/a | LKT Laboratories |
| Erythromycin | 329815 | 3415B88 | EMD Millipore |
| Kanamycin Sulfate | K4000-36 | n/a | Sigma |
| Rifampicin | 557303 | 644293 | Calbiochem |
| Spectinomycin Sulfate | S-9137 | 81 K12755 | Sigma |
| Tetracycline HCl | T-3383-25 | 20 K1279 | Sigma |
| Tobramycin | T-1783 | 124 K0948 | Sigma |
| Trimethoprim | T-7883 | 27H1015 | Sigma |